AstraZeneca to invest $50 billion for medicines manufacturing and R&D

AstraZeneca has recently announced a $50 billion of investment into the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.

Note that the cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides.

The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes:

• Expansion of our R&D facility in Gaithersburg, Maryland
• State-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
• Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California
• Continuous manufacturing expansion in Mount Vernon, Indiana
• Specialty manufacturing expansion in Coppell, Texas
• New sites to supply clinical trials
• Our growing research and development investment in novel medicines

Howard Lutnick, US Secretary of Commerce, said: “For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”

Governor Glenn Youngkin, Commonwealth of Virginia, said: “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain. Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”

---

---

Related Topics and Keywords

AstraZeneca